ЛИТЕРАТУРА
1. Iversen L.L. Role of transmitter uptake mechanisms in synaptic neurotransmission // Br. J. Pharmacol. 1971. Vol. 41. P. 571-591.
2. Nilsson O., Jakobsen A.M., Kolby L. et al. Importance of vesicle proteins in the diagnosis and treatment of neuroendocrine tumors // Ann. N. Y. Acad. Sci. 2004. Vol. 1014. P. 280-283.
3. Jakobsen A.M., Anderson P., Saglik G. et al. Differential expression of vesicular monoamine transporter (VMAT) 1 and 2 in gastrointestinal tumours // J. Pathol. 2001. Vol. 195, N 4. P. 463-472.
4. Kölby L., Bernhardt P., Levin-Jakobsen A.M. et al. Uptake of meta-iodobenzylguanidine in neuroendocrine tumours is mediated by vesicular monoamine transporters // Br. J. Cancer. 2003. Vol. 89, N 7. Р. 1383-1388.
5. Wieland D.M., Brown L.E., Tobes M.C. et al. Imaging the primate adrenal medulla with [123-J] and [131-J] metaiodobenzylguanidine: concise communication // J. Nucl. Med. 1981. Vol. 22. P. 358-364.
6. Pucar D., Markovic S. Nuclear medicine diagnosis of pheochromocytoma with metaiodobenzylguanidine // Srp. Arh. Celok Lek. 2002. Vol. 130, suppl. 2. P. 20-24.
7. van der Harst E., de Herder W.W., Bruining H.A. et al. [123I] Metaiodobenzylguanidine and [111In] Octreotide uptake in benign and malignant pheochromocytomas // J. Clin. Endocrinol. Metab. 2001. Vol. 86. P. 685-693.
8. Leung A., Shapiro B., Hattener R. et al. Specificity of radioiodinated MIBG for neural crest tumors in childhood // J. Nucl. Med. 1997. Vol. 38. P. 1352-1357.
9. Feldman J., Blinder R., Lucas K., Coleman E. Iodine-131 metaiodobenzylguanidine scintigraphy of carcinoid tumors // J. Nucl. Med. 1986. Vol. 27. P. 1691-1696.
10. Rufini V., Calcagni M.L., Baum R.P. Imaging of neuroendocrine tumors // Semin. Nucl. Med. 2006. Vol. 36, N 3. P. 228-247.
11. Prvulovich E.M., Stein R.C., Bomanji J.B. et al. Iodine-131 therapy of a patient with carcinoid liver metastases // J. Nucl. Med. 1998. Vol. 39. P. 1743-1745.
12. Breeman W.A.P., de Jong M., Kwekkeboom D.J. et al. Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspectives // Eur. J. Nucl. Med. 2001. Vol. 28. P. 1421-1429.
13. Kwekkeboom D.J., Krenning E.P. Somatostatin receptor imaging // Semin. Nucl. Med. 2002. Vol. 32, N 2. P. 84-91.
14. Hofland L.J., Lamberts S.W. Somatostatin receptor subtype expression in human tumors // Ann. Oncol. 2001. Vol. 12, suppl. 2. P. S31-S36.
15. Schillaci O., Scopionaro F., Angeletti S. et al. SPECT improves accuracy of receptor scintigraphy in abdominal carcinoid tumors // J. Nucl. Med. 1996. Vol. 37. P. 1452-1456.
16. Schillaci O., Spanu A., Scopionaro F. et al. Somatostatin receptor scintigraphy in liver metastatic detection from gastroenteropancreatic neuroendocrine tumors // J. Nucl. Med. 2003. Vol. 44. P. 359-368.
17. Dromain C., de Baere T., Lumbroso J. et al. Detection of liver metastases from endocrine tumors: a prospective comparison of somatostatin receptor scintigraphy, computed tomography, and magnetic resonance imaging // J. Clin. Оncol. 2005. Vol. 23. P. 70-78.
18. Lebtahi R., Cadiot G., Sarda L. et al. Clinical impact of somatostatin receptor scintigraphy in the management of patients with neuroendocrine gastroenteropancreatic tumors // J. Nucl. Med. 1997. Vol. 38. P. 853-858.
19. Kälkner K.-M., Janson E.T., Nillson S. et al. Somatostatin receptor scintigraphy in patients with carcinoid tumors: comparison between radioligand uptake and tumor markers // Cancer Res. 1995. Vol. 55. P. 5801-5804.
20. Dörr U., Räth U., Sautter-Bihl M.-L. et al. Improved visualization of carcinoid liver metastases by indium-111 pentreotide scintigraphy following treatment with cold somatostatin analogue // Eur. J. Nucl. Med. 1993. Vol. 20. P. 431-433.
21. Ezziddin S., Logvinski T., Yong-Hing C. et al. Factors predicting tracer uptake in somatostatin receptor and MIBG scintigaraphy of metastatic gastroenteropancreatic neuroendocrine tumors // J. Nucl. Med. 2006. Vol. 47. P. 223-233.
22. Hoefnagel C.A. Metaiodobenzylguanidine and somatostatin in oncology: role in the management of neural crest tumours // Eur. J. Nucl. Med. 1994. Vol. 21. P. 561-581.
23. Adams S., Baum R., Rink T. et al. Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours // Eur. J. Nucl. Med. 1998. Vol. 25. P. 79-83.
24. Pacak K., Eisenhofer G., Goldstein D.S. Functional imaging of endocrine tumors: role of positron emission tomography // Endocr. Rev. 2004. Vol. 25, N 4. P. 568-580.
25. Putzer D., Gabriel M., Kendler D. et al. Comparison of 68Ga-DOTA-Tyr3-octreotide and 18F-fluoro-L-dihydroxyphenylalanine positron emission tomographyin neuroendocrine tumor patients // Q. J. Nucl. Med. Mol. Imaging. 2010. Vol. 54. P. 68-75.
26. Treatment with tandem [90Y] DOTA-TATE and [177Lu] DOTA-TATE of neuroendocrine tumors refractory to conventional therapy: preliminary results // Q. J. Nucl. Med Mol. Imaging. 2010. Vol. 54. P. 84-91.